Bio-Techne Corporation (TECH) Financial Statements
Bio-Techne Corporation (TECH) reported trailing twelve-month revenue of $1.2B (down 0.4% year on year) and net income of $181.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $263.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TECHBio-Techne CorporationFollow TECH — free
—
Price chart with a free account
- Market cap
- 11.4B
- P/E TTM
- 63.1
- Dividend yield
- 0.4%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Jun 11 | FY2012 Jun 12 | FY2013 Jun 13 | FY2014 Jun 14 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Jun 20 | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Jun 23 | FY2024 Jun 24 | FY2025 Jun 25 | FY2026 Jun 26 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.29 | 0.31 | 0.31 | 0.36 | 0.45 | 0.50 | 0.56 | 0.64 | 0.71 | 0.74 | 0.93 | 1.11 | 1.14 | 1.16 | 1.22 | 1.22 | 1.22 | |
| Gross profit | 0.22 | 0.24 | 0.23 | 0.25 | 0.31 | 0.34 | 0.37 | 0.43 | 0.47 | 0.48 | 0.63 | 0.76 | 0.77 | 0.77 | 0.79 | 0.80 | 0.80 | |
| Research & development | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.09 | 0.09 | 0.10 | 0.10 | 0.09 | 0.09 | |
| Operating income | 0.16 | 0.17 | 0.00 | 0.16 | 0.15 | 0.15 | 0.12 | 0.14 | 0.15 | 0.16 | 0.24 | 0.30 | 0.30 | 0.21 | 0.10 | 0.25 | 0.25 | |
| Pre-tax income | 0.16 | 0.16 | 0.16 | 0.16 | 0.15 | 0.15 | 0.11 | 0.13 | 0.11 | 0.28 | 0.15 | 0.30 | 0.34 | 0.19 | 0.10 | 0.24 | 0.24 | |
| Income tax | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | -0.00 | 0.02 | 0.05 | 0.01 | 0.04 | 0.05 | 0.02 | 0.03 | 0.06 | 0.06 | |
| Net income | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 | 0.08 | 0.13 | 0.10 | 0.23 | 0.14 | 0.27 | 0.29 | 0.17 | 0.07 | 0.18 | 0.18 | |
| Diluted EPS ($) | 3.02 | 3.04 | 3.05 | 3.00 | 2.89 | 2.80 | 2.03 | 3.31 | 2.47 | 5.82 | 0.87 | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 | 1.15 | |
| Diluted shares (bn) | 0.037 | 0.037 | 0.037 | 0.037 | 0.037 | 0.037 | 0.037 | 0.038 | 0.039 | 0.039 | 0.162 | 0.164 | 0.162 | 0.161 | 0.160 | 0.157 | — |
USD billions · SEC XBRL
Bio-Techne Corporation — questions
- What is Bio-Techne Corporation's revenue?
- $1.2B over the twelve months to 2026-06-30, down 0.4% year on year, from its 10-Q and 10-K filings.
- What is Bio-Techne Corporation's net income?
- $181.9M over the twelve months to 2026-06-30.
- What is Bio-Techne Corporation's free cash flow?
- $263.2M over the twelve months to 2026-06-30.
- What are Bio-Techne Corporation's diluted earnings per share?
- $1.15 over the twelve months to 2026-06-30.
Every figure on this page comes from Bio-Techne Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.